1. Scrip
  2. >>Business

Coronavirus Update: Moderna Progesses To Phase II, Russia Approves Homegrown Antiviral

CanSino Has Produced Fuller Data

 
• By Scrip Team

Moderna maintains its lightning pace, but questions about its Phase III trial design remain.

US_Protest
Washington, DC, 30 May: Protests over the death of George Floyd have exploded across the US. The mass gatherings are worrying public health experts, including ex-FDA commissioner Scott Gottlieb, who says they could fuel a rise in COVID-19 infections.

The first participants have been dosed in the Moderna Inc.’s Phase II study of its novel coronavirus vaccine mRNA-1273.

The US biotech company is the focus of huge attention as a front-runner in the race to develop a vaccine against SARS-CoV-2, its rapid progress sustaining hope that

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Business

Takeda Plans US Investment But Sees Little Impact From Tariffs

 
• By Alaric DeArment

The Japanese drug maker is on track for three pivotal Phase III readouts and two regulatory submissions in 2025.

Q1 S&E In Brief: Tracking New Launches And Catalysts In Biopharma

 
• By Jessica Merrill and Joseph Haas

Neurocrine, Madrigal and Vanda updated investors on new drug launches, while Cytokinetics talked to investors about an FDA extension for aficamten.

Which Firms Are Most Exposed To Prasad’s Possible Accelerated Approvals Clampdown?

 
• By Andrew McConaghie

Vaccine and accelerated approvals are expected to face greater scrutiny under new CBER leader Vinay Prasad, but he has promised “no light switch change” to policy, giving some reassurance to companies whose share prices have been battered.

Building Up US Biopharma Manufacturing Will Require Investments In Talent

 
• By Jessica Merrill

Workforce development will be essential to meeting president Trump’s goal to return biopharma manufacturing to the US.

More from Scrip